Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
This phenomenon occurs because weight loss, particularly when substantial and occurring over a relatively short period, can mobilise uric acid from tissues and temporarily elevate serum uric acid levels, potentially triggering acute gout episodes in those predisposed to the condition
Leila Parand is an assistant clinical professor of neurology at the University of California, Los Angeles
Cross-Trial Context# Retatrutide's 24.2% weight loss at 48 weeks appears numerically superior to semaglutide's 14.9% at 68 weeks, but several factors complicate direct comparison: Trial phase : Phase 2 trials often yield more favorable results than Phase 3 (smaller, more controlled populations) Treatment duration : Semaglutide data are at 68-104 weeks
A separate analysis by background insulin regimen (basal, premixed or basal-bolus) was done for PIONEER 8 using the treatment policy estimand (regardless of trial product discontinuation or rescue medication use)
US$ 24.60
US$ 24.43
&srotate=0)
US$ 27.60
